Table 2 Correlations between levels of p16, p27 expression and clinico-pathological characteristics
| Variable | p16 | p27 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| low | high | n | p value | low | high | n | p value | ||||||
| N | % | n | % | n | % | n | % | ||||||
| pre-op PSA | < 5 | 10 | 71.4 | 4 | 28.6 | 14 | 0.252 | 12 | 85.7 | 2 | 14.3 | 14 | 0.397 |
| 5-10 | 36 | 75 | 12 | 25 | 48 | 0.104 | 39 | 81.2 | 9 | 18.8 | 48 | 0.215 | |
| > 10 | 8 | 100 | 0 | 0 | 8 | 0.180 | 8 | 100 | 0 | 0 | 8 | 0.534 | |
|
Gleason
score | ≤ 7 (3+4) | 21 | 72.4 | 8 | 27.6 | 29 | 0.565 | 25 | 86.2 | 4 | 13.8 | 29 | 1.000 |
| ≥ 7 (4+3) | 33 | 80.5 | 8 | 19.5 | 41 | 34 | 82.9 | 7 | 17.1 | 41 | |||
| pT stage | ≤ 2 | 34 | 80.9 | 8 | 19.1 | 42 | 0.394 | 37 | 88.1 | 5 | 11.9 | 42 | 0.328 |
| > 2 | 20 | 71.4 | 8 | 28.6 | 28 | 22 | 78.6 | 6 | 21.4 | 28 | |||
| PSA relapse | no | 24 | 72.7 | 9 | 27.3 | 33 | 0.572 | 27 | 81.8 | 6 | 18.2 | 33 | 1.000 |
| yes | 30 | 81.1 | 7 | 18.9 | 37 | 31 | 83.8 | 6 | 16.2 | 37 | |||